Guidance Point Advisors’s Biogen BIIB Stock Holding History

Guidance Point Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2	Closed	–	–	116
2021 Q3	$0	Buy	+2	New	+$656	﹤0.01%	418

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Guidance Point Advisors's BIIB Position: Q4 2021 in Review

Guidance Point Advisors sold out of Biogen (BIIB) in Q4 2021, closing a stake of 2 shares.

Guidance Point Advisors first reported a position in BIIB in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Guidance Point Advisors reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Guidance Point Advisors sold 2 Biogen shares in Q4 2021.
Guidance Point Advisors first reported a position in Biogen in Q3 2021 and held it in 1 quarter.
Guidance Point Advisors's Biogen position peaked at $0 in Q3 2021.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Guidance Point Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.